1-Boc-4-(4-氟苯氨基)-哌啶 | 288573-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-Boc-4-(4-氟苯氨基)-哌啶
• 中文别名: 1-BOC-4-(4-氟苯氨基)-哌啶
• 英文名称: tert-butyl 4-((4-fluorophenyl)amino)piperidine-1-carboxylate
• 英文别名: 1-(tert-Butoxycarbonyl)-4-[(4-fluorophenyl)amino]piperidine；1-Boc-4-(4-fluoro-phenylamino)-piperidine；tert-butyl 4-(4-fluoroanilino)piperidine-1-carboxylate
• CAS: 288573-56-8
• 化学式: C₁₆H₂₃FN₂O₂
• 分子量: 294.369
• InChiKey: TUYSUNKDSSHKHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(4-氟苯氨基)-哌啶 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 12.0h， 以84%的产率得到1-[(2S)-2-amino-3-methylbutanoyl]-N-(4-fluorophenyl)piperidin-4-amine dihydrochloride
  参考文献：
  名称：

  EP2258697

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氟苯胺 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 18.5h， 生成 1-Boc-4-(4-氟苯氨基)-哌啶
  参考文献：
  名称：

  The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an N-type Ca +2 channel blocker with oral activity for analgesia

  摘要：

  Our drug discovery efforts for N-type calcium channel blockers in the 4-piperidinylaniline series led to the discovery of an orally active analgesic agent 26. 1-[4-Dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine (26) showed high affinity to functionally block N-type calcium channels IC50 = 0.7 mu M in the IMR32 assay) and exhibited high efficacy in the anti-writhing analgesia test with mice (ED50 = 12 mg/kg by po and 4 mg/kg by iv). In this report, the rationale for the design, synthesis, biological evaluation, and pharmacokinetics of this series of blockers is described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00077-8

文献信息

• Triazinone compound and T-type calcium channel inhibitor
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US09403798B2

  公开（公告）日：2016-08-02

  There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

  提供了一种新型的三嗪酮化合物，该化合物具有优良的T型电压依赖性钙通道抑制活性，特别适用于治疗疼痛。公式(I)的化合物、该化合物的tautomer、药用可接受的盐或溶剂: 其中，每个取代基在说明或权利要求中有详细定义，例如，R1是H或C1-6烷氧基等，L1和L2各自独立为单键或NR2等，L3为C1-6亚烷基等，A为C6-14芳基或5至10元杂芳基，该芳基可被选配地取代等，B为C3-11环烷基等，D为C6-14芳基或5至10元杂芳基，该芳基可被选配地取代等。
• Cyclic amine compounds and pharmaceutical composition containing the same
  申请人：KOWA CO., LTD.

  公开号：US20040010147A1

  公开（公告）日：2004-01-15

  A cyclic amine compound represented by the following general formula (1): 1 wherein, R 1 , R 2 and R 3 each independently represent a hydrogen atom or an alkoxy group; W 1 and W 2 each independently represent N or CH; X represents O, NR 4 , CONR 4 or NR 4 CO; R 4 represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

  以下是通用公式（1）表示的一个环胺化合物： 其中， R 1 ，R 2 和R 3 分别独立地表示氢原子或烷氧基； W 1 和W 2 分别独立地表示N或CH； X表示O，NR 4 ，CONR 4 或NR 4 CO； R 4 表示氢原子，或烷基，芳基，杂芳基，芳基烷基或杂芳基烷基； l，m和n分别表示0或1的数字， 提供其盐和水合物。 这些化合物对细胞粘附和细胞浸润均具有抑制作用，并可用作抗哮喘剂，抗过敏剂，抗风湿剂，抗动脉硬化剂，抗炎剂，抗干燥综合征剂等。
• Piperazine Heteroaryl Derivatives as Gpr38 Agonists
  申请人：MacDonald Gregor James

  公开号：US20080312209A1

  公开（公告）日：2008-12-18

  The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Z, X and B are as defined in the specification. The compounds are partial or full agonists at the GPR38 receptor. Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.

  该发明提供了式（I）的化合物或其药学上可接受的盐， 其中R1、R2、R3、R4、R5、R6、Z、X和B如规范中所定义。这些化合物是GPR38受体的部分或全激动剂。还提供了包括这些化合物的药物组合物、制备这些化合物的方法、这些化合物的用途以及涉及这些化合物的方法。
• [EN] TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2017058716A1

  公开（公告）日：2017-04-06

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers or congenital diseases. Specific cancers and congenital disease includes those that are mediated by YAP/TAZ.

  本文提供了包含所述化合物的药物组合物，用于治疗癌症或先天性疾病。具体的癌症和先天性疾病包括那些由YAP/TAZ介导的疾病。
• Synthesis of 5-oxyquinoline derivatives for reversal of multidrug resistance
  作者：Torsten Dittrich、Nils Hanekop、Nacera Infed、Lutz Schmitt、Manfred Braun

  DOI：10.3762/bjoc.8.193

  日期：——

  The inhibition of ABC (ATP binding cassette) transporters is considered a powerful tool to reverse multidrug resistance. Zosuquidar featuring a difluorocyclopropyl-annulated dibenzosuberyl moiety has been found to be an inhibitor of the P-glycoprotein, one of the best-studied multidrug efflux pumps. Twelve 5-oxyisoquinoline derivatives, which are analogues of zosuquidar wherein the dibenzosuberyl-piperazine moiety is replaced by either a diarylaminopiperidine or a piperidone-derived acetal or thioacetal group, have been synthesized as pure enantiomers. Their inhibitory power has been evaluated for the bacterial multidrug-resistance ABC transporter LmrCD and fungal Pdr5. Four of the newly synthesized compounds reduced the transport activity to a higher degree than zosuquidar, being up to fourfold more efficient than the lead compound in the case of LmrCD and about two times better for Pdr5.

  ABC（ATP结合盒）转运蛋白的抑制被认为是逆转多药耐药的有力工具。发现了一种具有二氟环丙基环戊二苯亚基结构的佐苏奎达，它被发现是P-糖蛋白的抑制剂，后者是研究最充分的多药外流泵之一。已合成了十二种5-氧异喹啉衍生物，它们是佐苏奎达的类似物，其中二苯亚基-哌嗪结构被二芳胺哌啶或哌啶酮衍生的缩醛或硫缩醛基团替代，这些衍生物均为纯对映异构体。它们的抑制力已经针对细菌多药耐药ABC转运蛋白LmrCD和真菌Pdr5进行了评估。新合成的四种化合物中有四种比佐苏奎达更有效地降低了转运活性，在LmrCD的情况下高达四倍，对于Pdr5则提高了约两倍。